Oncotelic Therapeutics Inc. has unveiled preclinical data showing its Deciparticle nanomedicine platform can significantly reduce gastrointestinal drug accumulation for cancer treatments. The platform reliably formulates diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into uniform, IV-ready nanoparticles. Current preclinical pharmacokinetic data show that Sapu003, the intravenous Deciparticle formulation of Everolimus (Afinitor), cuts down gastrointestinal drug accumulation by up to 67-fold compared to oral dosing. These advancements highlight a quickly expanding immunology and oncology pipeline built on modular, cGMP-ready nanomedicine engineering.
The company unveiled new data at the 2025 San Antonio Breast Cancer Symposium, highlighting that its Deciparticle platform can package even water-resistant drugs into smaller, uniform nanoparticles suitable for intravenous use. The platform shows high-level compatibility across different therapeutic categories, with all five main macrolide mTOR inhibitors—including temsirolimus, sirolimus, ridaforolimus, Everolimus (Afinitor), and umirolimus—forming stable, monodisperse particles. Oncotelic Therapeutics is rapidly emerging as a key player in next-generation drug delivery with a scalable nanotechnology platform that can transform immunology and oncology treatment paradigms. The company's clinical-stage nanomedicine, Sapu Nano, serves as the foundation for this expanding pipeline. The latest developments and updates relating to OTLC are available through various industry channels.
The implications of this technology extend beyond improved drug delivery to potentially enhanced patient quality of life through reduced gastrointestinal side effects. By minimizing drug accumulation in the digestive system while maintaining therapeutic efficacy, the platform addresses a significant challenge in cancer treatment management. This advancement represents progress toward more targeted therapies that could improve treatment adherence and outcomes for patients undergoing immunology and oncology treatments. The ability to reliably formulate diverse hydrophobic drugs into uniform nanoparticles marks a substantial step forward in nanomedicine applications for cancer care.
